YTS109

N/A

Report date: 2026/03/09 20:02:04

Base Information

Drug NameYTS109
Drug Alias NameYTS-109YTS109
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsImmunoglobulin G4-Related DiseaseAntiphospholipid SyndromeAutoimmune Diseases +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChina Immunotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChina Immunotech Co Ltd
Inactive CompaniesN/A
Active IndicationsImmunoglobulin G4-Related DiseaseAntiphospholipid SyndromeAutoimmune Diseases +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A